Galecto (NASDAQ:GLTO) vs. Pasithea Therapeutics (NASDAQ:KTTA) Financial Survey

Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Volatility and Risk

Galecto has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Institutional & Insider Ownership

14.2% of Galecto shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 11.9% of Galecto shares are owned by company insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Galecto and Pasithea Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galecto	0	0	1	0	3.00
Pasithea Therapeutics	0	0	0	0	0.00

Galecto currently has a consensus price target of $10.00, indicating a potential upside of 116.45%. Given Galecto’s stronger consensus rating and higher possible upside, equities analysts plainly believe Galecto is more favorable than Pasithea Therapeutics.

Profitability

This table compares Galecto and Pasithea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galecto	N/A	-76.96%	-66.59%
Pasithea Therapeutics	N/A	-81.57%	-74.31%

Valuation & Earnings

This table compares Galecto and Pasithea Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galecto	N/A	N/A	-$38.35 million	($19.14)	-0.24
Pasithea Therapeutics	N/A	N/A	-$15.96 million	N/A	N/A

Summary

Galecto beats Pasithea Therapeutics on 6 of the 9 factors compared between the two stocks.

About Galecto

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.